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1.  Introduction
Cancer patients receive not only modern Western 
medical care but also other treatments, commonly 
known as complementary and alternative medicine 
(CAM) [1]. CAM is more prevalent in Asia due to the 
unique use of traditional medical care.
Within traditional medicine, oriental medicine 
is one of the most widely used in many countries 
for various diseases. Traditional medicine has not 
been able to develop methods of cancer treatment 
on the same scale as Western medicine because most 
of the traditional medical theories were developed 
during times when the idea of cancer was not defini-
tively formulated.
Recently, with the advancement of CAM around 
the world, there have been many clinical trials and 
developments in cancer therapy using traditional 
medical. Pharmacopuncture therapy is a new form 
of therapy derived from a combination of herbal 
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medicine and acupuncture therapy. Minute amounts 
of herbal extract are injected in affected areas 
(acupoints or intravenous) to induce a therapeutic 
response by maximizing the efficacies of acupunc-
ture and herbal medicine [2].
In Korean medicine, ginseng (Panax ginseng 
C.A. Meyer) has long been used as a general tonic 
or an adaptogen to promote longevity and enhance 
bodily functions. It has also been claimed to be 
effective in combating stress, fatigue, oxidants, 
diabetes mellitus and cancer [3].
The literature on Cultivated Wild Ginseng Phar-
macopuncture (CWGP) comprises anecdotal evi-
dence, case reports of cancer treatment, phase I 
clinical trials for healthy volunteers, cell culture 
experiments, animal experiments and mechanism 
studies [4−14]. Evidence of dosage, treatment period 
and cancer type are not sufficient to support its anti-
cancer efficacy even though some Korean oriental 
medical doctors believe that intravenous infusion or 
point injection of CWGP is effective for terminally ill 
cancer patients. We decided to conduct a descrip-
tive pilot study for heterogeneous cancer patients 
in advanced stages to collect clinical evidence for 
the effects of CWGP on advanced cancer.
2. Materials and Methods
2.1. Patients
Seven patients were recruited between August, 
2007 and June, 2008. We explained treatment to 
these patients and obtained their informed consent. 
This study proceeded at East-West Cancer Center. 
Eligibility criteria included the following:
(1) Histological or radiological diagnosis of progres-
sive malignant tumor. The patient also was not 
subject to conventional therapies including sur-
gery, anticancer drugs, radiation, embolization, 
hormone therapy, immunotherapy and tradi-
tional oriental medicine;
(2) Eastern Cooperative Oncology Group (ECOG) 
score ≤ 3;
(3) Measurable malignant disease using the inter-
national standard provided by the Response 
Evaluation Criteria in Solid Tumors (RECIST), in-
cluding complete/partial response, progressive/
stable disease);
(4) Completed anti-cancer drugs and/or radiation 
treatment 4 weeks prior to participation;
(5) Recovered from any side-effects of anti-cancer 
drugs and/or radiation treatment;
(6) Possess proper bone marrow function (peripheral 
absolute granulocyte count > 150 ˜  109/L, plate-
let count > 100 ˜  109/L);
(7) Proper liver function (bilirubin ≤ 1.5 mg/dL, 
serum glutamic pyruvic transaminase or serum 
glutamic oxaloacetic transaminase < 3 ˜  normal) 
and kidney function (creatinine ≤ 1.5 mg/dL).
2.2. Treatment
Patients received CWGP 20 mL/day by intravenous 
infusion. One cycle was composed of 2 weeks (14 
days).
2.3. Endpoints
Two endpoints were set to evaluate the result: (1) 
survival rate, including overall survival (from ini-
tial administration of CWGP to death), survival or 
discontinued follow-up (from initial administration 
of CWGP to final check or discontinued follow-up), 
and Kaplan-Meier analysis; (2) response rate, as 
measured by the International standard provided 
by RECIST as complete response, partial response, 
progressive disease and stable disease.
2.4.  Tumor measurement for response rate
Computed tomography (CT) scan was performed in 
patients at the start of the study and initial tumor 
size was recorded. After every two cycles (4 weeks), 
another CT scan was performed. RECIST criteria for 
solid tumors were used in our study. Compared with 
initial tumor size, a decrease of 30% or greater in 
size was confirmed as partial response, an increase 
of 20% or greater was confirmed as progressive dis-
ease, and neither was confirmed as stable disease.
3.  Results
3.1.  Patient characteristics
Subjects in this study consisted of six males (85.7%) 
and one female (14.3%). There were three patients 
with lung cancer (42.9%), two with colorectal cancer 
(28.6%), one with stomach cancer (14.3%) and one 
with malignant mesothelioma (14.3%). Two patients 
were in stage III (28.6%) and five patients were in 
stage IV (71.4%; Table 1).
3.2.  Overall survival
In Figure 1, the median for 20 mL CWGP total sur-
vival period was 544 days. Minimum survival was 
26 days and the maximum survival was 898 days. 
One year survival rate was 57.1% (4/7). Figure 2 is 
a comparison of survival times between patients 
with ECOG ≤ 2 versus patients with ECOG = 3. This ob-
servation demonstrated that patients with ECOG ≤ 2 
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Table 1  Patient characteristics
Gender Male 6
 Female 1
Tumor site Lung (NSCLC) 3
 Colorectum 2
 Stomach 1
 Malignant mesothelioma 1
Stage III 2
 IV 5
ECOG 1 2
 2 2
 3 3
Prior therapy Yes 1
 No 6
Age (yr) Median 56 (47−63)
NSCLC = non-small cell lung carcinoma; ECOG = Eastern 
Cooperative Oncology Group.
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Figure 1   Overall patient survival rate. A total of seven 
patients participated. One year survival rate was 57.1% 
and median survival time was 544 days (26 − 718 days).
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Figure 2   Survival rates for Eastern Cooperative Oncology 
Group (ECOG) score. Three patients with ECOG ≥ 3 all died 
within 1 year and four patients with ECOG ≤ 2 all survived 
over 1 year. Group 1: ECOG ≤ 2, Group 2: ECOG ≥ 3.
all survived the trial duration (4/4), but patients 
with ECOG = 3 all died during this period (3/3). 
Median survival days were 657 vs. 56, respectively.
3.3.  Response rate
The data of each patient is shown in Tables 2 and 3. 
Two patients were not evaluated due to drop out 
after the first and second cycles of treatment and no 
follow up CT scans were obtained. In the remaining 
five patients, two patients showed progressive dis-
ease and three patients experienced stable disease.
3.4.  Cases of stable disease
Case 1 (No.7) was a 67-year-old woman diagnosed 
with non-small cell lung carcinoma (NSCLC; ade-
nocarcinoma) on June 25, 2007. Tumor stage was IIIB 
Table 2  Patient summaries
No.
 Primary 
ECOG Stage Cycle 
Dose
 Response TTP (d) OS (d)
 Treatment 
 impression    (mL/d)    after CWGP
1 Colon 3 4 2 20 NE NE 26 Unknown
2 Mesothelioma 3 4 2 20 PD 28 56 Unknown
3 NSCLC 3 4 1 20 NE NE 140 Unknown
4 AGC 2 4 13 20 SD 272 544 None
5 Colon 2 4 3 20 PD 28 596 Unknown
6 NSCLC 1 3 13 20 SD 301 718 None
7 NSCLC 1 3 21 20 SD 198 898 None
NE = not evaluated; TTP = time to progress; OS = overall survival; ECOG = Eastern Cooperative Oncology Group (0 = fully active; 
1 = restricted in physically strenuous activity; 2 = up and about more than 50% of waking hours; 3 = limited self-care confined to bed 
or chair more than 50% of waking hours; 4 = totally confined to bed or chair; 5 = dead); CWGP = cultivated wild ginseng pharmaco-
puncture; PD = progressive disease; NSCLC = non-small cell lung carcinoma; AGC = advanced gastric carcinoma; SD = stable disease.
(T2N3M0) with a mass (5 cm ˜  4 cm) in the left lower 
lobe of the lung and accompanying lymph node en-
largements. Because of her old age, she refused con-
ventional therapy. Instead, she initiated CWGP 
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Table 3  Results of radiology review
No. Tumor Modality Date Response
1 Colon   Not evaluated
2 Mesothelioma Chest and abdomen CT 2007-10-20 Pleural large mass
   2007-11-16 Increased size and number (PD)
3 NSCLC   Not evaluated
4 AGC Abdomen CT 2007-12-10 Large stomach mass and multiple
    metastasis
   2008-01-09 No interval change since LE (SD)
   2008-02-09 Slightly increased since LE
   2008-03-08 No interval change since LE
   2008-04-05 No interval change since LE
   2008-05-03 No interval change since LE
   2008-06-04 No interval change of stomach mass
    and increased liver metastasis since 
    LE (PD)
   2008-07-05 No interval change since LE
   2008-09-08 No interval change of stomach mass 
    and increased liver mets LE
    Increased size since 2008-09-08
5 Colon PET-CT chest, abdomen 2007-10-20 Mass in rectum and liver, 
  and pelvis CT  lung metastasis
   2007-11-26 More increased rectal mass and liver, 
    lung metastasis (PD)
6 NSCLC Chest CT 2007-11-01 Mass in LLL
   2007-11-29 No interval change since LE (SD)
   2007-12-24 No interval change since LE
   2008-01-21 No interval change since LE
   2008-04-08 No interval change since LE
   2008-05-07 No interval change since LE
   2008-07-07 Increased mass size since LE (PD)
   2008-09-23 Increased mass size with 10cm
7 NSCLC Chest CT 2007-06-11 Mass in LLL
   2007-08-10 Slight increase in LLL since LE (SD)
   2007-09-28 No interval change since LE
   2007-12-04 No interval change since LE
   2008-01-02 No interval change since LE
   2008-04-07 No interval change since LE
   2008-07-02 No interval change since LE
   2008-09-29 No interval change since LE
  PET-CT 2007-06-29 Hypermetabolic LLL lesion with both 
    mediastinal and both supraclavicular LAP
   2008-01-31 No interval change of LLL mass. Right 
    adrenal gland metastasis was suggested (PD)
   2008-05-07 No interval change of LLL mass. Suggested 
    right adrenal gland metastasis increased
CT = computed tomography; PD = progressive disease; NSCLC = non-small cell lung carcinoma; AGC = advanced gastric carcinoma; 
LE = last evaluation; SD = stable disease; PET-CT = positron emission tomography-computed tomography; LLL = left lower lobe; 
LAP = lymphadenopathy.
treatment as a CAM from July 6, 2007. Administration 
of CWGP was 20 mL daily (21 cycles). Cancer growth 
was halted for 29 weeks (7 months). But positron 
emission tomography-computed tomography on 
January 31, 2008 revealed a metastatic lesion of the 
adrenal gland. Subsequent PET-CT on May 7, 2008 
also showed an increase in the size of the metastatic 
lesion in the adrenal gland.
Case 2 (No.6) was a 63-year-old man diagnosed 
with non-small cell lung carcinoma on October 31, 
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2007. Tumor stage was IIIA (T1N2). He refused con-
ventional therapy as he wished to be treated with 
CAM even though health providers recommended 
surgical therapy for him. CWGP treatment was ini-
tiated from November 26, 2007. Administration of 
CWGP was 20 mL daily (13 cycles). Cancer growth 
was halted for 33 weeks (8 months), but chest CT on 
July 6, 2008 showed progression of the disease.
Case 3 (No. 4) was a 55-year-old man diagnosed 
by CT as having stomach cancer metastasized to 
the liver on October 9, 2007. Tumor stage was IV. 
CWGP treatment was initiated from December 12, 
2007. Administration of CWGP was 20 mL daily (13 
cycles). Cancer growth was halted for 26 weeks (6.5 
months), but abdominal CT on June 4, 2008 showed 
progression of the disease.
4.  Discussion
Cultivated wild Ginseng (Panax ginseng C.A. Meyer), 
a Korean traditional medicinal herb, has been used 
clinically in Korea and other Asian countries for thou-
sands of years [3].
Recently, there have been controversies concern-
ing the usefulness of ginseng in cancer therapy. Most 
studies claimed that the pharmacological effects of 
ginseng are attributed to its bioactive constituents 
such as ginsenosides, saponins, phytosterols, pep-
tides, polysaccharides, fatty acids, polyacetylenes, 
vitamins and minerals [12]. However, in a previous 
study, wild ginseng pharmacopuncture was experi-
mentally shown to have anti-tumor effects, while its 
intravenous safety showed no difference from that 
of saline [4,8,15].
Produced by a distillation process, CWGP is com-
posed of over 99% water and less than 1% wild gin-
seng. However, the present study did not verify its 
effective compounds. In the production process, less 
than 1% was found to contain flavonoids by gas 
chromatography-mass spectrometry. There are many 
types of flavonoids, such as quercetin, hesperidin 
and anthocyanidins (cyanidins, delphinidin, malvidin, 
pelargonidin, peonidin and petunidin). Flavonoids, as 
a group of compounds, interfere with inflammation 
and carcinogenesis in various ways. Several flavo-
noids quench reactive oxygen species. Other flavo-
noids suppress the pro-inflammatory and growth 
promoting gene mediated by nuclear factor kappa B. 
Flavonoids also interfere with signal transduction 
pathways, which reduce tumor initiation and pro-
motion [16].
Delphinidin, an anthocyanidin flavonoid, inter-
feres with signal transduction pathways. Low con-
centrations of delphinidin in vitro have been shown 
to inhibit vascular endothelial growth factor (VEGF)-
induced tyrosine phosphorylation of VEGFR-2, leading 
to the inhibition of downstream signaling and VEGF-
induced activation of ERK-1/2 signaling [17]. In the 
present study, it is not clear whether the effect of 
CWGP treatment came via flavonoid activity; how-
ever, a connection with some flavonoid compo-
nents may be a possibility.
Six previous studies have investigated the anti-
cancer effect of CWGP. The first study [6] concluded 
that CWGP did not show a significant anti-cancer 
effect in B16/F10 melanoma, but inhibited the dam-
age to epithelial cells seen with doxorubicin. The 
second study [7] concluded that cultivated wild 
ginseng herbal acupuncture caused negligible tox-
icity. All experimental groups showed significant 
increase in survival rate following the anti-cancer 
effects on a sarcoma-180 cancer cell line [7]. In the 
third study [8], inhibitory effects of ginseng against 
cancer growth in a case of hepatic metastasis were 
also observed when colon 26-L5 carcinoma cells 
were injected via the hepatic portal vein. The level 
of cytokine IL-4, which stimulates Th2, showed a 
significant increase [8]. The fourth study [9] de-
scribed a clinical case which concluded that CWGP 
could be an effective measure for multiple metas-
tatic cancer patients with hepatocellular carcinoma. 
The fifth study [10] was conducted in apoptosis in-
duced A549 human lung cancer cell lines which 
showed that the cell destruction efficacy of CWGP 
improved when pH and electrolytes were adjusted. 
Additionally, various concentrations of CWGP have 
been experimentally demonstrated to induce apo-
ptosis in lung cancer cells [11].
Some findings pertaining to CWGP treatment were 
observed preceding this trial. Intravenous infusion 
of CWGP 20 mL/day was shown not to be useful in 
prolonging the survival rate of poor ECOG patients. 
By contrast, a possibility of increased survival was 
seen in good ECOG patients. For our small number of 
participants, differences in cancer type, stage and 
ECOG score made it difficult to make any conclusions 
about the efficacy of CWGP on the response rate, but 
given that three of seven participants showed stable 
disease, future studies into CWGP may be warranted.
In this study, three advanced cancer patients (two 
NSCLC, one advanced gastric cancer) showed sta-
ble disease that even when it became progressive, 
were with few complications. These patients lived 
well over 1 year in spite of their poor prognosis, 
and maintained good quality of life. This observa-
tion suggests that dosage and treatment periods 
should be over 20 mL/day and 13 cycles long, respec-
tively. The efficacy of CWGP in NSCLC would be 
interesting to investigate in the next stage of stud-
ies, given the accumulated evidence of CWGP use 
for the treatment of this cancer to date. Al though 
further large scale study are needed, CWGP was 
found to be an ef fective treatment intervention 
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for two NSCLC patients and one advanced gastric 
carcinoma patient in this study.
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